OTCMKTS:DCTHD - Delcath Systems Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started Previous Close$3.00Today's Range$3.00 - $3.1452-Week Range$1.22 - $63,000.0030Volume12,654 shsAverage Volume79,871 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company's system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company's focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver. Receive DCTHD News and Ratings via Email Sign-up to receive the latest news and ratings for DCTHD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:DCTHD Previous SymbolNASDAQ:DCTH CUSIPN/A Webwww.delcath.com Phone212-489-2100Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees46 Outstanding SharesN/AMarket Cap$0.00 OptionableNot Optionable Delcath Systems (OTCMKTS:DCTHD) Frequently Asked Questions What is Delcath Systems' stock symbol? Delcath Systems trades on the OTCMKTS under the ticker symbol "DCTHD." When did Delcath Systems' stock split? How did Delcath Systems' stock split work? Delcath Systems's stock reverse split on Monday, November 6th 2017. The 1-350 reverse split was announced on Friday, November 3rd 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, November 3rd 2017. An investor that had 100 shares of Delcath Systems stock prior to the reverse split would have 0 shares after the split. How were Delcath Systems' earnings last quarter? Delcath Systems, Inc. (OTCMKTS:DCTHD) released its quarterly earnings results on Friday, November, 11th. The medical device company reported ($231.00) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1,151.50) by $920.50. The medical device company earned $0.44 million during the quarter. During the same period last year, the business posted ($686.00) EPS. View Delcath Systems' Earnings History. Has Delcath Systems been receiving favorable news coverage? Headlines about DCTHD stock have trended negative recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Delcath Systems earned a media sentiment score of -2.5 on InfoTrie's scale. They also gave media headlines about the medical device company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the stock's share price in the next several days. Who are some of Delcath Systems' key competitors? Some companies that are related to Delcath Systems include 3M (MMM), Becton Dickinson and (BDX), Stryker (SYK), Boston Scientific (BSX), Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ResMed (RMD), ABIOMED (ABMD), DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), Haemonetics (HAE), ICU Medical (ICUI), Penumbra (PEN) and Insulet (PODD). Who are Delcath Systems' key executives? Delcath Systems' management team includes the folowing people: Roger G. Stoll Ph.D., Chairman of the Board (Age 74)Jennifer K. Simpson Ph.D., President, Chief Executive Officer, Director (Age 48)Barbra C. Keck, Chief Financial Officer, Secretary (Age 39)John Purpura, Executive Vice President - Global Head of Operations (Age 55)Simon C. Pedder Ph.D., Director (Age 56)William Dodge Rueckert, Independent Director (Age 64)Marco Taglietti M.D., Independent Director (Age 57) How do I buy shares of Delcath Systems? Shares of DCTHD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Delcath Systems' official website? The official website for Delcath Systems is http://www.delcath.com. How can I contact Delcath Systems? Delcath Systems' mailing address is 1633 BROADWAY SUITE 22C, NEW YORK NY, 10019. The medical device company can be reached via phone at 212-489-2100 or via email at [email protected] MarketBeat Community Rating for Delcath Systems (OTCMKTS DCTHD)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 173 (Vote Outperform)Underperform Votes: 171 (Vote Underperform)Total Votes: 344MarketBeat's community ratings are surveys of what our community members think about Delcath Systems and other stocks. Vote "Outperform" if you believe DCTHD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DCTHD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/16/2019 by MarketBeat.com StaffFeatured Article: What are CEFs?